Author: Lee, Yong-ho; Kim, Jae Hyeon; Kim, So Ra; Jin, Heung Yong; Rhee, Eun-Jung; Cho, Young Min; Lee, Byung-Wan
Title: Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness Document date: 2016_11_8
ID: 4fwp1dnl_11
Snippet: All continuous variables were expressed as the mean ± standard deviation (SD). The AST, ALT, and TG values were log transformed, because value distributions were skewed. Student's t-tests and Pearson's χ 2 tests were used for continuous and categorical variables, respectively, to evaluate any differences according to lobeglitazone responsiveness. A responder to lobeglitazone was defined as any individual who showed a decrease in CAP after treat.....
Document: All continuous variables were expressed as the mean ± standard deviation (SD). The AST, ALT, and TG values were log transformed, because value distributions were skewed. Student's t-tests and Pearson's χ 2 tests were used for continuous and categorical variables, respectively, to evaluate any differences according to lobeglitazone responsiveness. A responder to lobeglitazone was defined as any individual who showed a decrease in CAP after treatment. Changes in clinico-laboratory parameters, including CAP and HbA1C values, after lobeglitazone treatment were evaluated using a paired t-test. We performed correlation analyses to examine the relationship between changes in CAP values and clinico-laboratory parameters at baseline and after treatment. Multivariate linear regression analysis was performed to assess the association between CAP value changes and various clinico-laboratory parameters. The results are expressed as values of standardized (STD) β-coefficients and P values. A twosided P value < 0.05 was considered significant. All statistical analyses were conducted using SPSS for Windows software (version 20.0; SPSS Inc., Chicago, IL, USA).
Search related documents:
Co phrase search for related documents- CAP value and HbA1C value: 1
- CAP value and linear regression: 1
- CAP value and lobeglitazone responder: 1
- CAP value and lobeglitazone treatment: 1, 2, 3, 4
- CAP value change and clinico laboratory: 1
- CAP value change and linear regression: 1
- CAP value change and lobeglitazone treatment: 1
- categorical continuous variable and continuous variable: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- clinico laboratory and linear regression: 1
- clinico laboratory and lobeglitazone treatment: 1
- continuous variable and correlation analysis: 1
- continuous variable and HbA1C value: 1
- continuous variable and linear regression: 1, 2, 3, 4, 5
- correlation analysis and β coefficient: 1, 2, 3
- correlation analysis and linear regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- correlation analysis perform and linear regression: 1, 2
- difference evaluate and linear regression: 1
- HbA1C value and linear regression: 1
- HbA1C value and lobeglitazone treatment: 1
Co phrase search for related documents, hyperlinks ordered by date